Abstract
This study compared the single administration of human parathyroid hormone [hPTH(1-34)] or bisphosphonate cimadronate (YM-175), and concurrent therapy with both of these agents for restoration of lost bone mineral density (BMD) in ovariectomized (OVX) rats. Animals were untreated for 4 weeks after surgery, and then injected s.c. with vehicle (OVX+V), hPTH(l-34) (30μg/kg) (OVX+P), YM-175 (5μg/kg) (OVX+Y), or a combination of these two (OVX+P+Y), 3 days a week, for 8 weeks, and killed. BMD of distal, middle, and total femur were determined by dual-energy X-ray absorptiometry (DXA). BMD of distal and total femur, but not of midfemur, decreased at both 4 weeks and 12 weeks after ovariectomy. In the distal femoral BMD, although OVX+Y failed to restore lost BMD in OVX rats, either OVX+P or OVX+P+Y could reverse BMD lost due to OVX. Midfemoral BMD was unchanged through OVX or both single treatments, whereas this parameter was increased only in OVX+P+Y. These results suggest that concurrent treatment with PTH and YM-175 results in a bone anabolic effect not only in cancellous bone but also in cortical bone.
Similar content being viewed by others
References
Tam CS, Heersche JNM, Murray TM, Parsons JA (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506–512
Gunness-Hey M, Hock JM (1984) Increased trabecular bone mass in rats treated with synthetic human parathyroid hormone. Metab Bone Dis 5:177–181
Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65–72
Jerome CP (1994) Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J Bone Miner Res 9:933–942
Oxlund H, Ejersted C, Andreassen TT, Torring O, Nilsson MHL (1993) Parathyroid hormone (1-34) and (1-84) stimulate bone formation both periosteum and endosteum. Calcif Tissue Int 53:394–399
Reeve J, Meunier PJ, Parsons JA, Bernard M, Buvoet OLM, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik O, Vismans FJFE, Potts JT (1980) Anabolic effects of human PTH on trabecular bone in involutional osteoporosis: A multicenter trial. Br Med J 280:1340–1344
Slovik D, Rosenthal DI, Doppelt SH, Potts JT, Daly MA, Cambell JA, Neer RM (1986) Restoration of spinal bone in osteoporotic men by treatment with human PTH (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1:377–382
Hesch RD, Prokop M, Busch U, Delling G, Rittinghaus EF (1990) Dramatic increase of bone mass and turnover in osteoporosis by combined 1-38 hPTH and calcitonin therapy. In: Takahashi HE (ed) Bone morphometry. Nishimura, Niigata, p 598
Reeve J, Davies UM, Hesp R, McNally E, Katz D (1990) Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. Br Med J 301:314–318
Reeve J, Bradbeer JN, Arlot ME, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP, Zanelli JM, Meunier PJ (1991) hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biomechanical, kinetic and histological responses. Osteoporosis Int 1:162–170
Hori M, Uzawa T, Morita K, Noda T, Takahashi H, Inoue J (1988) Effect of human parathyroid hormone (PTH(1-34)) on experimental osteopenia of rats induced by ovariectomy. Bone Miner 3:193–199
Liu CC, Kalu DN (1990) Human PTH prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 3:973–982
Kimmel DB, Bozzato RP, Kronis KA, Kwong P, Recker RR (1993) The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584
Yamamoto N, Takahashi HE, Tanizawa T, Fujimoto R, Hara T, Tanaka S (1993) Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1-34) administration. Bone Mineral 23:333–342
Shen V, Dempster DW, Mellish RWE, Birchman R, Horbet W, Lindsay R (1992) Effects of combined and separate intermittent administration of low-dose parathyroid hormone fragment (1-34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 50:214–220
Wronski TJ, Yen C-F, Qi H, Dann LM (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132:823–831
Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15:51–58
Wronski TJ, Yen CF, Scott KS (1991) Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 6:387–394
Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6:339–346
Jee WSS, Tang LY, Ke HZ, Setterberg RB, Kimmel DB (1993) Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: Dynamic histomorphometry of changes in bone mass. Bone 14:493–498
Hodsmann AB (1989) Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: A clinical and bone histomorphometric study. Bone Miner 5:201–212
Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate L (1989) Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int 44:74–79
Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Janover MJ, Mysiw JW, Kohse. L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79
Fleisch H (1993) Actions. In: Fleisch H (ed) Bisphosphonates in bone disease: From the laboratory to the patient. Stampfli, Berne, pp 33–49
Fujimoto R, Nii A (1990) Effect of disodium dihydrogen (cycloheptilamino) methylene bisphosphonate (YM-175) on the bone formation and resorption in rats and dogs. J Bone Min Res 5[Suppl 11]: S157
Wronski TJ, Walsh CC, Ignaszewski LA (1986) Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 7:119–123
Wronski TJ, Cintron M, Dann LM (1988) Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 43:179–183
Wronski TJ, Dann LM, Scott KS, Cintron M (1989) Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360–366
Danielsen CC, Mosekilde L, Svenstrup B (1993) Cortical bone mass, composition, and mechanical properties in female rats in regulation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue Int 52:26–33
Author information
Authors and Affiliations
About this article
Cite this article
Mashiba, T., Tanizawa, T., Takahashi, H.E. et al. Effects of single and concurrent intermittent administration of human parathyroid hormone and bisphosphonate cimadronate on bone mineral densities of femur in ovariectomized rats. J Bone Miner Metab 13, 17–22 (1995). https://doi.org/10.1007/BF01771800
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01771800